Published online before print July 17, 2003, doi: 10.1161/01.RES.0000086986.35568.63
© 2003 American Heart Association, Inc.
Integrative Physiology |
Type 5 Adenylyl Cyclase Disruption Alters Not Only Sympathetic But Also Parasympathetic and Calcium-Mediated Cardiac Regulation
From the Cardiovascular Research Institute, Department of Cell Biology & Molecular Medicine and Department of Medicine, University of Medicine and Dentistry of New Jersey–New Jersey Medical School, Newark, NJ.
Correspondence to Stephen F. Vatner, MD, and Yoshihiro Ishikawa, MD, PhD, Department of Cell Biology & Molecular Medicine, MSB G-609, UMDNJ–New Jersey Medical School, Newark, NJ 07101-1709. E-mail vatnersf{at}umdnj.edu and ishikayo@umdnj.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In a genetically engineered mouse line with disruption of type 5 adenylyl cyclase (AC5-/-), a major cardiac isoform, there was no compensatory increase in other isoforms of AC in the heart. Both basal and isoproterenol (ISO)-stimulated AC activities were decreased by 30% to 40% in cardiac membranes. The reduced AC activity did not affect cardiac function (left ventricular ejection fraction [LVEF]) at baseline. However, increases in LVEF after ISO were significantly attenuated in AC5-/- (P<0.05, n=11). Paradoxically, conscious AC5-/- mice had a higher heart rate compared with wild-type (WT) mice (613±8 versus 523±11 bpm, P<0.01, n=14 to 15). Muscarinic agonists decreased AC activity, LVEF, and heart rate more in WT than in AC5-/-. In addition, baroreflex-mediated, ie, neuronally regulated, bradycardia after phenylephrine was also attenuated in AC5-/-. The carbachol-activated outward potassium current (at -40 mV) normalized to cell capacitance in AC5-/- (2.6±0.4 pA/pF, n=16) was similar to WT (2.9±0.3 pA/pF, n=27), but calcium (Ca2+)-mediated inhibition of AC activity and Ca2+ channel function were diminished in AC5-/-. Thus, AC5-/- attenuates sympathetic responsiveness and also impairs parasympathetic and Ca2+-mediated regulation of the heart, indicating that those actions are not only regulated at the level of the receptor and G-protein but also at the level of type 5 AC.
Key Words: ß-adrenergic receptors • muscarinic receptors • calcium channels • knockout • adenylyl cyclase isoforms
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cardiac rate and contractility are regulated by both sympathetic and parasympathetic mechanisms. Sympathetic stimulation leads to coupling of the ß-adrenergic receptor (ß-AR) and Gs, the G-protein responsible for stimulating activity of adenylyl cyclase (AC), a membrane-bound enzyme that catalyzes the conversion of ATP to cAMP, thereby stimulating protein kinase A and ultimately increasing cardiac contractility.1–4 Parasympathetic stimulation counteracts these effects through the activation of the muscarinic receptor and Gi, the G-protein that can inhibit cardiac contractility and rate.5 These sympathetic and parasympathetic mechanisms constitute the two arms of autonomic regulation of the heart. A considerable amount of data exists relating to autonomic regulation at the level of their respective receptors and G-proteins. A novel concept to consider, central to this study, is whether parasympathetic regulation also occurs at the level of AC.
The goal of the present investigation was to determine the regulation of cardiac contraction and rate by type 5 AC in response to ß-AR stimulation and also whether it can modulate parasympathetic function in vivo. Whereas all prior studies have examined these questions in vitro6 or in vivo7,8 using pharmacological stimulation or even by overexpressing isoforms of AC in the heart,9–11 we selected the approach of targeted disruption of AC. However, this experimental design is complicated by the fact that AC consists of 9 mammalian transmembrane isoforms.4,12–14 We selected type 5 AC to knockout in the mouse (AC5-/-), because this isoform is one of the most prominent in adult cardiac tissue and is expressed negligibly in other organs except for the brain.4,15,16 Furthermore, whereas all of the 9 AC isoforms so far isolated can be linked to Gs stimulation, Gi inhibition is associated with only a few AC isoforms, eg, types 1, 5, and 6 AC, and has been observed only in vitro.17,18 In addition, type 5 AC also is inhibited directly by low concentrations of calcium (Ca2+).19 Therefore, we also examined the regulation of AC activity by Ca2+.20 The specific questions we addressed in this study are whether elimination of type 5 AC decreases either baseline cardiac function or heart rate (HR), impairs sympathetic stimulation, or alters parasympathetic modulation of cardiac function and HR. We addressed these questions using a combination of in vivo and in vitro approaches, eg, by measuring cardiac function echocardiographically, measuring HR in conscious mice, measuring Ca2+ channel activity of isolated myocytes, and assessing AC activity in vitro in cardiac membranes.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Generation of Knockout Mice
All mice were 129/SvJ-C57BL/6 mixed-background littermates from F1 heterozygote crosses. All experiments were performed in 4- to 6-month-old homozygous AC5-/- and wild-type (WT) littermates. This study was approved by the Animal Care and Use Committee at New Jersey Medical School (see the online supplement, available at http://www.circresaha.org, for additional detail).
RNase Protection Assay
Partial fragments of mouse AC cDNA clones for each isoform (types 1 through 9) were obtained by polymerase chain reaction. A human 28S ribosomal RNA probe was used as an internal control. RNase protection assay was performed using the RPA III kit (Ambion) as suggested by the manufacturer.
AC Assay
Hearts were dissected from the mice, and membrane preparations were prepared as described previously.21 For the study of Ca2+ inhibition, the membranes were treated first with EGTA to extract the endogenous Ca2+ before the assay. Free Ca2+ concentrations were obtained with the use of 200-µmol/L EGTA buffers, as described previously.22,23
Physiological Studies
ECG wires, a jugular vein catheter for drug infusion, and a femoral artery catheter for arterial pressure monitoring were implanted under anesthesia as described previously.24,25 Measurements of left ventricular ejection fraction (LVEF) were taken using echocardiography under anesthesia with 2.5% tribromoethanol (0.010 to 0.015 mL per gram of body weight) injected intraperitoneally.26,27 Intravenous infusion of ISO (0.04 µg/kg per min IV for 5 minutes) was performed using an infusion pump. To examine the responses to a muscarinic agonist, acetylcholine (ACh) (25 mg/kg IP) was coadministered intraperitoneally during the intravenous infusion of ISO (0.04 µg/kg per min). In addition, in conscious mice, ACh (0.01 and 0.05 mg/kg), atropine (0.25, 1, and 2 mg/kg), or verapamil (0.75 mg/kg) was administered intravenously, and the ECG was recorded. A recovery period of 15 minutes was allowed for the HR to return to baseline before administering the next drug. To examine HR responses to baroreflex hypertension, phenylephrine (0.2 mg/kg IV) was infused and the ECG and arterial pressure were measured.
Pathology
The pathological examination included assessment of body weight, heart weight, and light microscopy of H&E-stained sections of the left ventricle.
Radioligand Binding Assays and Western Blotting
Radioligand binding assays for ß-AR were conducted using the above membrane preparations and 125I-cyanopindolol as previously described.28 Western blotting was conducted using commercially available antibodies, except for type 5 AC (see the online data supplement).
Electrophysiological Studies
Whole-cell currents were recorded using patch-clamp techniques as previously described.29–32 (See the online data supplement for additional detail.)
Statistical Analysis
All data are reported as mean±SEM. Comparisons between AC5-/- and WT values were made using a Student’s t test. For statistical analysis of data from multiple groups, one-way ANOVA was used with Bonferroni post hoc test. P<0.05 was taken as a minimal level of significance.
An expanded Materials and Methods section can be found in the online data supplement available at http://www.circresaha.org.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Targeted Disruption of the Type 5 AC Gene
The type 5 AC gene was disrupted in mice using homologous recombination (Figure 1A). Mice were genotyped by Southern blotting using genomic DNA from tail biopsies (Figure 1B). mRNA expression of type 5 AC was undetectable in AC5-/- (Figure 1C). Type 5 AC cardiac protein was undetectable in AC5-/- (Figure 1D). The growth, general appearance, and heart size of the AC5-/- were similar to WT (Table). Normal cardiac architecture was demonstrated on light microscopy (see the online data supplement).
|
|
No Compensatory Increase in the Other Isoforms of AC
We then examined whether there were compensatory increases in the expression of the other isoforms of AC in AC5-/-. Because AC isoform–specific antibodies that can convincingly determine the level of protein expression of all the isoforms are not available, we quantitated the mRNA expression of the AC isoforms by RNase protection assays. cRNA of the 28S rRNA was used as an internal control. Type 2, 3, 4, 6, 7, and 9 AC were detected readily but not increased (Figure 2), whereas types 1 and 8 were hardly detectable (data not shown), indicating that type 6 AC, a homologue of type 5 AC in the heart, could not compensate for the type 5 AC deficiency.
|
AC Activity Was Decreased in the Heart of AC5-/- In Vitro
AC activity was decreased in AC5-/- relative to that in WT by 35±4% (basal), 27±5% (ISO), 27±2% (GTP
S), and 40±5% (forskolin) (Figure 3A). More specifically, ISO increased AC activity by 78±6 pmol/15 min per mg in WT but only 64±4 pmol/15 min per mg in AC5-/-, indicating that the response to ISO was attenuated in AC5-/-. These data indicate that type 5 AC is responsible for 
30% to 40% of total AC activity in the mouse heart. Carbachol (10 µmol/L), a muscarinic agonist, decreased ISO-stimulated AC activity by 21±3% in WT, but this was hardly detectable in AC5-/- (Figure 3B), indicating that muscarinic (Gi-induced) inhibition of the AC activity is markedly attenuated in AC5-/-.
|
Regulation of AC Activity by Free Ca2+
To investigate the modulation of AC activity by free Ca2+, we examined cAMP production in membranes from the hearts of WT and AC5-/- at different Ca2+ concentrations in the presence of ISO (100 µmol/L ISO+100 µmol/L GTP) (Figure 3C). The ISO-stimulated AC activity was inhibited by increasing concentrations of Ca2+ as expected in WT. The Ca2+ inhibition of AC activity was impaired in AC5-/-. The reduction in magnitude of inhibition was most apparent in AC5-/-, ie, in the submicromolar range of Ca2+ (Figure 3C).
Basal Cardiac Function Was Not Decreased, but the Response to ISO and Muscarinic Inhibition of ISO Were Impaired
We originally hypothesized that cardiac function, both basal and ISO-stimulated, would be depressed in AC5-/-. The cardiac responses to intravenous ISO on LVEF in AC5-/- were attenuated as expected (Figure 4). However, baseline cardiac function was not different between WT and AC5-/- (LVEF: WT versus AC5-/-, 70±1.2% versus 70±1.5%, n=10 to 11; fractional shortening: WT versus AC5-/-, 33±0.9% versus 33±1.0%, n=10 to 11) (Table). Muscarinic inhibition of ISO-stimulated cardiac function, as measured by LVEF, was prominent in WT, as expected, but was attenuated in AC5-/- (Figure 4), suggesting that muscarinic inhibition of ß-adrenergic stimulation was impaired. This conclusion is based on the finding that ACh in the presence of ISO reduced LVEF less in AC5-/- than WT (P<0.05). However, because the baseline during ISO was lower in AC5-/-, the level achieved after ACh was not significantly different.
|
Parasympathetic (Muscarinic) Control of HR
Baseline HR was significantly elevated in conscious AC5-/- (WT versus AC5-/-: 523±11 versus 613±8 bpm, P<0.01, n=14 to 15) (Table). The increase in HR after muscarinic receptor blockade by atropine (1 mg/kg IV) in WT was not observed in AC5-/- (Figure 5A). Muscarinic stimulation in conscious WT with ACh (0.01 mg/kg IV) decreased HR by 15% but significantly less (1.3%) in AC5-/- (Figure 5B). However, high doses of ACh (0.05 mg/kg IV) decreased HR similarly in both WT and AC5-/-. At the higher doses of ACh, it is possible that the lack of AC5 inhibition was overwhelmed. In contrast, verapamil, which decreases HR through a nonmuscarinic mechanism, reduced HR in AC5-/- and WT similarly (-33±10 versus -36±10 bpm). These findings suggest that muscarinic inhibition was impaired in the conscious state in the absence of ISO stimulation in AC5-/-.
|
To confirm that muscarinic, and therefore parasympathetic, neural regulation of the heart was changed, we injected phenylephrine (0.2 mg/kg IV) to elevate arterial pressure transiently through vasoconstriction and to induce baroreflex-mediated slowing of HR. Phenylephrine increased systolic arterial pressure similarly in both WT and AC5-/-. However, the degree of HR slowing was significantly less in AC5-/- than in WT (Figure 5C), suggesting that the baroreflex, most likely through its parasympathetic control, was attenuated in AC5-/-.
ß-AR Binding Assay and Western Blotting
The expression of ß-AR was not different (Kd: WT 102±17 pmol/L, AC5-/- 115±29 pmol/L; Bmax: WT 36±5 fmol/mg, AC5-/- 31±4 fmol/mg; n=5, P=NS), nor was the expression of Gs
, Gi, Gq, Gß, ß-ARK, 1-AR, or muscarinic receptor type 2 (Figure 6A).
|
K+ Current Activity
To determine whether enhanced baseline HR and blunted response to muscarinic agonists in AC5-/- are attributable to changes in the K+ channel, we examined muscarinic receptor–coupled K+ channel currents in atrial myocytes.30,33–36 Figure 6B shows representative atrial K+ channel currents induced by carbachol (10 µmol/L) recorded in WT and AC5-/- myocytes. Rapid application of carbachol elicited an outward K+ current via Gi proteins. The carbachol-induced currents rose quickly to a peak and then decayed slowly to a steady level. The peak amplitude and decay time were similar between WT and AC5-/- myocytes (Figure 6C). These results indicate that coupling between muscarinic receptors and the Gi-gated K+ channel is not altered in AC5-/- myocytes.
Basal Ca2+ Channel Activity and Response to ISO
Peak inward ICa amplitude (with 5 mmol/L EGTA in the pipette solution), normalized to cell capacitance (ICa density), was similar in myocytes isolated from AC5-/- (7.1±0.3 pA/pF, n=69) and WT (6.7±0.3 pA/pF, n=55). Half decay time of ICa at +10 mV was 21.9±1.4 and 21.0±1.4 ms for AC5-/- and WT, respectively. These data suggest that changes in AC activity did not directly influence Ca2+ channel density or inactivation kinetics. In previous studies, we have proposed that AC activity and subsequent cAMP synthesis, which modulate Ca2+ channel activity, are regulated by Ca2+ influx through the channel.20,37 We thus compared the effects of ISO on ICa using procedures designed to modulate the cytoplasmic Ca2+ concentration with two different Ca2+ chelators, EGTA and BAPTA, the latter of which have faster Ca2+ binding kinetics, and with the use of extracellular barium (Ba2+), which permeates the Ca2+ channel but does not trigger Ca2+ of the sarcoplasmic reticulum (SR). Figure 7A shows a typical example of the effect of ISO (1 µmol/L) on ICa in WT and AC5-/-. In both groups, ISO increased the current amplitude at all test potentials and also shifted the I-V relationships toward more negative potentials. However, in the presence of ISO, peak ICa amplitude in AC5-/- was significantly smaller (-19.6±2.0 pA/pF, P<0.05). Analysis of cumulative dose-response effects of ISO (Figure 7B) revealed that, when either BAPTA or Ba2+ was used, the maximum response of the Ca2+ channel to ISO was significantly augmented (2.4-fold) compared with cells dialyzed with EGTA (1.7-fold), suggesting that Ca2+ inhibited Ca2+ channel activity in WT.20 In contrast, the responses of AC5-/- myocytes to ISO were essentially the same in all three conditions (1.5-fold), suggesting that Ca2+-mediated inhibition of Ca2+ channel activity was markedly diminished in AC5-/-. These results suggest that intracellular Ca2+ can inhibit ß-AR–mediated activation of Ca2+ channels, presumably through directly inhibiting cardiac AC activity,20 and that type 5 AC is a major target of this inhibition (Figure 7B).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We developed a mouse model with disruption of a major AC isoform (type 5) in the heart. It was predictable that increases in cardiac function in response to ISO would be diminished in AC5-/-, as was demonstrated in this study. Indeed, the decrease in cardiac responsiveness to ISO in vivo paralleled the data in vitro on AC activity. Because overexpression of type 5 AC in the heart enhanced cardiac function,11 we had expected that baseline cardiac function and HR would be reduced in AC5-/-, which was not observed. Despite the decrease in AC activity, basal cardiac function and HR were not decreased in AC5-/-. Actually, HR was significantly elevated in conscious AC5-/-. Although we do not know all the mechanisms that contribute to the increase in cardiac rate, we propose at least three mechanisms that are impaired in AC5-/-: muscarinic inhibition of AC activity, baroreflex restraint of HR, and Ca2+-mediated inhibition of AC activity.
Because the elevated HR was not likely attributable to enhanced sympathetic tone, ie, sympathetic responses were attenuated in AC5-/- in both in vivo and in vitro experiments, we hypothesized that it was attributable, at least in part, to the loss of parasympathetic inhibition, because type 5 AC is a major Gi-inhibitable isoform in the adult heart.17,18 To confirm this, we demonstrated that muscarinic stimulation, which inhibits cardiac function and HR, was attenuated in AC5-/- both in the presence and absence of enhanced ß-AR stimulation with ISO. Conversely, atropine increased HR in WT but not in AC5-/-, supporting the concept that the higher baseline HR was attributable to the loss of parasympathetic restraint. Furthermore, we demonstrated that arterial baroreflex slowing of HR, which occurs through parasympathetic nerves, was also blunted in AC5-/-. Therefore, at any given arterial pressure, there is less baroreflex restraint, resulting in elevated HR. Taken together, these data provide convincing evidence in vivo that type 5 AC exerts a major role in parasympathetic regulation of cardiac function in addition to its key role in sympathetic regulation, which has been recognized for some time. Thus, AC-mediated parasympathetic modulation of ventricular function and atrial function, ie, HR, must be considered along with the more widely recognized mechanisms involving muscarinic modulation of K+ channel activity30,38 and muscarinic regulation at the level of membrane receptors, or Gi. To support this conclusion, the K+ current in atrial myocytes and the expression of G proteins, ß-ARK, muscarinic receptor type 2, and ß- and 1-AR were not altered in AC5-/-. Finally, it is also conceivable that the impaired Ca2+ inhibition of AC also contributes to the increased HR at baseline.
To conclude that tachycardia in AC5-/- was attributable to the loss of parasympathetic restraint, it is important to rule out the possibility that some other compensatory pathway did not cause the tachycardia. This possibility is unlikely for several reasons. First, the increase in HR is not compensatory but is actually opposite the prediction that reduced contractility and HR would be expected from disruption of AC. Although unlikely, it is still possible that the resetting autonomic activity in the brain, or some mechanism at the level of Ca2+ channels, could be involved. Type 5 AC is also located in the striatum of the brain, and disrupting this isoform of AC does alter dopaminergic transmission in the brain.39,40 However, it is more likely that parasympathetic stimulation leads to activation of muscarinic receptors and Gi to inhibit type 5 AC in the heart, which results in restraint on baseline HR. In the absence of type 5 AC, this restraint is lost and HR rises, as we observed in the AC5-/- mice in this investigation. It is important to note that the bradycardia resulting from pharmacologic muscarinic inhibition with ACh was attenuated in AC5-/-, indicating that the mechanism is localized to the heart and does not reside in the CNS. In additional support of this conclusion are the complementary in vitro data from cardiac membranes. HR is thought to be regulated at the level of the muscarinic receptor, or Gi, or GIRK.36 In the present investigation, coupling between muscarinic receptors and GIRK was not altered in AC5-/-. In view of the major alteration in muscarinic control in AC5-/-, we conclude that cardiac rate of contractility is also regulated at the level of AC. In support of this concept, a recent study suggested that muscarinic inhibition of ß1-AR stimulation may occur at the level of cAMP41 and that ß1-AR and type 5 AC are located in the same subcellular fraction.42
In cardiac muscle, Ca2+ influx through the L-type Ca2+ channel is the primary pathway for initiation and maintenance and for the modulation of contractility by catecholamines. The increase in ICa by the ß-adrenergic agonist ISO occurs via a cascade of events leading to protein kinase A–mediated phosphorylation of components associated with the Ca2+ channel. In turn, cardiac AC is regulated negatively by low concentrations of Ca2+.19,20 This mechanism was also impaired in AC5-/-. The extent to which this mechanism is impaired in AC5-/- must be interpreted cautiously, because small changes in experimental conditions can influence the magnitude of the results. Our finding suggested that under physiological conditions, an increase in Ca2+ entry and inhibition of type 5 AC, leading to decreased phosphorylation and thus activity of the Ca2+ channel, can work synergistically to provide an intrinsic feedback mechanism for cellular Ca2+ homeostasis. Thus, because of the lack of Ca2+-inhibitable type 5 AC in AC5-/-, this negative feedback inhibition of the L-type Ca2+ channel may be lost. This loss may account for, at least in part, the maintained cardiac function in AC5-/-. It is also important to consider the possibility that differences in SR loading and Ca2+ handling may have affected the response to ISO. However, in previous studies,20,37 we found in mouse ventricular myocytes that AC activity and subsequent cAMP synthesis, which modulate Ca2+ channel activity, are regulated by the Ca2+ entering through the Ca2+ channel rather than by Ca2+ released from the SR stores.
Another consideration is potential changes in calmodulin levels, which could regulate Ca2+-dependent Ca2+ channel inactivation.43 However, AC5-/- mice did not exhibit changes in Ca2+ channel amplitude or inactivation time course. Furthermore, calmodulin content assessed by Western blotting did not change in the AC5-/- (data not shown).
In summary, because type 5 AC is the major AC isoform expressed in the adult mouse heart, it was surprising to find no effect on baseline cardiac function but rather an increase in HR despite reduced baseline AC activity. Both the increased basal HR and blunted baroreflex-mediated bradycardia may be related to a loss of parasympathetic restraint and reduced Ca2+ regulation of AC. Other mechanisms, not yet identified, may also play a role in mediating these results. Thus, type 5 AC regulates cardiac inotropy and chronotropy through the parasympathetic arm of the autonomic nervous system as well as through the sympathetic arm. Therefore, these new mechanisms for regulation of parasympathetic/sympathetic interactions and Ca2+-mediated regulation conveyed by this specific AC isoform in the heart will likely have broad significance for the understanding of the pathophysiology and treatment of heart failure as well as in normal cardiac regulation.
|
Acknowledgments |
|---|
This work was supported in part by NIH grants HL59729, HL61476, HL67724, HL65183, HL65182, HL69020, HL59139, AG14121, and HL33107 and by American Heart Association grants 9940187N, 9950673N, and 0020323U. Y.I. is a recipient of the Established Investigator Award of the American Heart Association.
|
Footnotes |
|---|
Original received March 14, 2003; revision received July 8, 2003; accepted July 8, 2003.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Murray KJ, Reeves ML, England PJ. Protein phosphorylation and compartments of cyclic AMP in the control of cardiac contraction. Mol Cell Biochem. 1989; 89: 175–179.[Medline] [Order article via Infotrieve]
2. Federman AD, Conklin BR, Schrader KA, Reed RR, Bourne HR. Hormonal stimulation of adenylyl cyclase through Gi-protein ß subunits. Nature. 1992; 356: 159–161.[CrossRef][Medline]
[Order article via Infotrieve]
3. Ishikawa Y. Regulation of cAMP signaling by phosphorylation. Adv Second Messengers Phosphoprotein Res. 1998; 32: 99–120.[Medline] [Order article via Infotrieve]
4. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol. 2001; 41: 145–174.[CrossRef][Medline] [Order article via Infotrieve]
5. Caulfield MP. Muscarinic receptors: characterization, coupling and function. Pharmacol Ther. 1993; 58: 319–379.[CrossRef][Medline] [Order article via Infotrieve]
6. Nagata K, Communal C, Lim CC, Jain M, Suter TM, Eberli FR, Satoh N, Coluci WS, Apstein CS, Liao R. Altered ß-adrenergic signal transduction in nonfailing hypertrophied myocytes from Dahl salt-sensitive rats. Am J Physiol Heart Circ Physiol. 2000; 279: H2502–H2508.
7. Kudej RK, Iwase M, Uechi M, Vatner DE, Oka N, Ishikawa Y, Shannon RP, Bishop SP, Vanter SF. Effects of chronic ß-adrenergic receptor stimulation in mice. J Mol Cell Cardiol. 1997; 29: 2735–2746.[CrossRef][Medline] [Order article via Infotrieve]
8. Vatner DE, Sato N, Galper JB, Vatner SF. Physiological and biochemical evidence for coordinate increases in muscarinic receptors and Gi during pacing-induced heart failure. Circulation. 1996; 94: 102–107.
9. Lipskaia L, Defer N, Esposito G, Hajar I, Garel MC, Rockman HA, Hanoune J. Enhanced cardiac function in transgenic mice expressing a Ca2+-stimulated adenylyl cyclase. Circ Res. 2000; 86: 795–801.
10. Gao MH, Lai NC, Roth DM, Zhou J, Zhu J, Anzai T, Dalton N, Hammond HK. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation. 1999; 99: 1618–1622.
11. Tepe NM, Lorenz JN, Yatani A, Dash R, Kranias EG, Dorn GW, Liggett SB. Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte ß-adrenergic signalling. Biochemistry. 1999; 38: 16706–16713.[CrossRef][Medline] [Order article via Infotrieve]
12. Ishikawa Y, Homcy CJ. The adenylyl cyclases as integrators of transmembrane signal transduction. Circ Res. 1997; 80: 297–304.
13. Tang WJ, Hurley JH. Catalytic mechanism and regulation of mammalian adenylyl cyclases. Mol Pharmacol. 1998; 54: 231–240.
14. Hurley JH. Structure, mechanism, and regulation of mammalian adenylyl cyclase. J Biol Chem. 1999; 274: 7599–7602.
15. Tobise K, Ishikawa Y, Holmer SR, Im MJ, Newell JB, Yoshi H, Fujita M, Susannie EE, Homcy CJ. Changes in type VI adenylyl cyclase isoform expression correlate with a decreased capacity for cAMP generation in the aging ventricle. Circ Res. 1994; 74: 596–603.
16. Espinasse I, Iourgenko V, Defer N, Samson F, Hanoune J, Mercadier JJ. Type V, but not type VI, adenylyl cyclase mRNA accumulates in the rat heart during ontogenic development: correlation with increased global adenylyl cyclase activity. J Mol Cell Cardiol. 1995; 27: 1789–1795.[CrossRef][Medline] [Order article via Infotrieve]
17. Taussig R, Iniguez-Lluhi JA, Gilman AG. Inhibition of adenylyl cyclase by Gi. Science. 1993; 261: 218–221.
18. Dessauer CW, Tesmer JJ, Sprang SR, Gilman AG. Identification of a Gi binding site on type V adenylyl cyclase. J Biol Chem. 1998; 273: 25831–25839.
19. Cooper DMF, Mons N, Karpen JW. Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature. 1995; 374: 421–424.[CrossRef][Medline] [Order article via Infotrieve]
20. Sako H, Sperelakis N, Yatani A. Ca2+ entry through cardiac L-type Ca2+ channels modulates ß-adrenergic stimulation in mouse ventricular myocytes. Pflügers Arch. 1998; 435: 749–752.[CrossRef][Medline] [Order article via Infotrieve]
21. Ishikawa Y, Sorota S, Kiuchi K, Shannon RP, Komamura K, Katsushika S, Vatner DE, Vatner SF, Homcy CJ. Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced heart failure in dogs. J Clin Invest. 1994; 93: 2224–2229.[Medline] [Order article via Infotrieve]
22. Boyajian CL, Garritsen A, Cooper DMF. Bradykinin stimulates Ca2+ mobilization in NCB-20 cells leading to direct inhibition of adenylylcyclase: a novel mechanism for inhibition of cAMP production. J Biol Chem. 1991; 266: 4995–5003.
23. Cooper DMF. Regulation of Ca2+-sensitive adenylyl cyclases by calcium ion in vitro and in vivo. Methods Enzymol. 1994; 238: 71–81.[Medline] [Order article via Infotrieve]
24. Iwase M, Uechi M, Vatner DE, Asai K, Shannon RP, Kudej RK, Wagner TE, Wight DC, Patrick TA, Ishikawa Y, Homcy CJ, Vatner SF. Cardiomyopathy induced by cardiac Gs overexpression. Am J Physiol. 1997; 272: H585–H589.[Medline]
[Order article via Infotrieve]
25. Uechi M, Asai K, Osaka M, Smith A, Sato N, Wagner TE, Ishikawsa Y, Hayakawa H, Vatner DE, Shannon RP, Homcy CJ, Vatner SF. Depressed heart rate variability and arterial baroreflex in conscious transgenic mice with overexpression of cardiac Gs. Circ Res. 1998; 82: 416–423.
26. Hart CY, Burnett JC, Redfield MR. Effects of avertin versus xylazine-ketamine anesthesia on cardiac function in normal mice. Am J Physiol Heart Circ Physiol. 2001; 281: H1938–H1945.
27. Roth DM, Swaney JS, Dalton ND, Gilpin EA, Ross JJ. Impact of anesthesia on cardiac function during echocardiography in mice. Am J Physiol Heart Circ Physiol. 2002; 282: H2134–H2140.
28. Gaudin C, Ishikawa Y, Wight DC, Mahdavi V, Nadal-Ginard B, Wanger TE, Vatner DE, Homcy CJ. Overexpression of Gs protein in the hearts of transgenic mice. J Clin Invest. 1995; 95: 1676–1683.[Medline]
[Order article via Infotrieve]
29. Yatani A, Brown AM, Schwartz A. Bepridil block of cardiac calcium and sodium channels. J Pharmacol Exp Ther. 1986; 237: 9–17.
30. Yatani A, Codina J, Brown AM, Birnbaumer L. Direct activation of mammalian atrial muscarinic potassium channels by GTP regulatory protein Gk. Science. 1987; 235: 207–211.
31. Masaki H, Sato Y, Luo W, Kranias EG, Yatani A. Phospholamban deficiency alters inactivation kinetics of L-type Ca2+ channels in mouse ventricular myocytes. Am J Physiol. 1997; 272: H606–H612.[Medline] [Order article via Infotrieve]
32. Mitarai S, Reed TD, Yatani A. Changes in ionic currents and ß-adrenergic receptor signaling in hypertrophied myocytes overexpressing Gq. Am J Physiol Heart Circ Physiol. 2000; 279: H139–H148.
33. Breitwieser GE, Szabo G. Uncoupling of cardiac muscarinic and ß-adrenergic receptors from ion channels by a guanine nucleotide analogue. Nature. 1985; 317: 538–540.[CrossRef][Medline] [Order article via Infotrieve]
34. Pfaffinger PJ, Martin JM, Hunter DD, Nathanson NM, Hille B. GTP-binding proteins couple cardiac muscarinic receptors to a K channel. Nature. 1985; 317: 536–538.[CrossRef][Medline] [Order article via Infotrieve]
35. Logothetis DE, Kurachi Y, Galper J, Neer EJ, Clapham DE. The ß subunits of GTP-binding proteins activate the muscarinic K+ channel in heart. Nature. 1987; 325: 321–326.[CrossRef][Medline]
[Order article via Infotrieve]
36. Wickman K, Nemec J, Gendler SJ, Clapham DE. Abnormal heart rate regulation in GIRK4 knockout mice. Neuron. 1998; 20: 103–114.[CrossRef][Medline] [Order article via Infotrieve]
37. Sako H, Green SA, Kranias EG, Yatani A. Modulation of cardiac Ca2+ channels by isoproterenol studied in transgenic mice with altered SR Ca2+ content. Am J Physiol. 1997; 273: C1666–C1672.[Medline] [Order article via Infotrieve]
38. Wickman K, Clapham DE. Ion channel regulation by G proteins. Physiol Rev. 1995; 75: 865–885.
39. Lee KW, Hong JH, Choi IY, Che Y, Lee JK, Yang SD, Song CW, Kang HS, Lee JH, Noh JS, Shin HS, Han PL. Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase. J Neurosci. 2002; 22: 7931–7940.
40. Iwamoto T, Okumura S, Iwatsubo K, Kawabe J, Ohtsu K, Sakai I, Hashimoto Y, Izumitani A, Sango K, Ajiki K, Toya Y, Umemura S, Goshima Y, Arai N, Vatner SF, Ishikawa Y. Motor dysfunction in type 5 adenylyl cyclase-null mice. J Biol Chem. 2003; 278: 16936–16940.
41. Aprigliano O, Rybin VO, Pak E, Robinson RB, Steinberg SF. ß1- and ß2-adrenergic receptors exhibit differing susceptibility to muscarinic accentuated antagonism. Am J Physiol. 1997; 272: H2726–H2735.[Medline] [Order article via Infotrieve]
42. Rybin VO, Xu X, Lisanti MP, Steinberg SF. Differential targeting of ß-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. J Biol Chem. 2000; 275: 41447–41457.
43. Peterson BZ, DeMaria CD, Adelman JP, Yue DT. Calmodulin is the Ca2+ sensor for Ca2+-dependent inactivation of L-type calcium channels. Neuron. 1999; 22: 549–558.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  C.-L. Hu, R. Chandra, H. Ge, J. Pain, L. Yan, G. Babu, C. Depre, K. Iwatsubo, Y. Ishikawa, J. Sadoshima, et al. Adenylyl cyclase type 5 protein expression during cardiac development and stress Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1776 - H1782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Lyashkov, T. M. Vinogradova, I. Zahanich, Y. Li, A. Younes, H. B. Nuss, H. A. Spurgeon, V. A. Maltsev, and E. G. Lakatta Cholinergic receptor signaling modulates spontaneous firing of sinoatrial nodal cells via integrated effects on PKA-dependent Ca2+ cycling and IKACh Am J Physiol Heart Circ Physiol, September 1, 2009; 297(3): H949 - H959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Kapiloff, L. A. Piggott, R. Sadana, J. Li, L. A. Heredia, E. Henson, R. Efendiev, and C. W. Dessauer An Adenylyl Cyclase-mAKAP{beta} Signaling Complex Regulates cAMP Levels in Cardiac Myocytes J. Biol. Chem., August 28, 2009; 284(35): 23540 - 23546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Okumura, T. Tsunematsu, Y. Bai, Q. Jiao, S. Ono, S. Suzuki, R. Kurotani, M. Sato, S. Minamisawa, S. Umemura, et al. Type 5 adenylyl cyclase plays a major role in stabilizing heart rate in response to microgravity induced by parabolic flight J Appl Physiol, July 1, 2008; 105(1): 173 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tang, M. H. Gao, N. C. Lai, A. L. Firth, T. Takahashi, T. Guo, J. X.-J. Yuan, D. M. Roth, and H. K. Hammond Adenylyl Cyclase Type 6 Deletion Decreases Left Ventricular Function via Impaired Calcium Handling Circulation, January 1, 2008; 117(1): 61 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Chester and V. J. Watts Adenylyl Cyclase 5: A New Clue in the Search for the "Fountain of Youth"? Sci. Signal., November 20, 2007; 2007(413): pe64 - pe64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Okumura, D. E. Vatner, R. Kurotani, Y. Bai, S. Gao, Z. Yuan, K. Iwatsubo, C. Ulucan, J.-i. Kawabe, K. Ghosh, et al. Disruption of Type 5 Adenylyl Cyclase Enhances Desensitization of Cyclic Adenosine Monophosphate Signal and Increases Akt Signal With Chronic Catecholamine Stress Circulation, October 16, 2007; 116(16): 1776 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Willoughby and D. M. F. Cooper Organization and Ca2+ Regulation of Adenylyl Cyclases in cAMP Microdomains Physiol Rev, July 1, 2007; 87(3): 965 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rottlaender, J. Matthes, S. F. Vatner, R. Seifert, and S. Herzig Functional Adenylyl Cyclase Inhibition in Murine Cardiomyocytes by 2'(3')-O-(N-Methylanthraniloyl)-Guanosine 5'-[{gamma}-Thio]triphosphate J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 608 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Circ. Res., October 13, 2006; 99(8): 816 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Iwatsubo, S. Minamisawa, T. Tsunematsu, M. Nakagome, Y. Toya, J. E. Tomlinson, S. Umemura, R. M. Scarborough, D. E. Levy, and Y. Ishikawa Direct Inhibition of Type 5 Adenylyl Cyclase Prevents Myocardial Apoptosis without Functional Deterioration J. Biol. Chem., September 24, 2004; 279(39): 40938 - 40945. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||